Inhibikase Q2 net loss widens to $19.6M; Phase 3 PAH trial advances with $50M financing

Inhibikase Therapeutics, Inc.

Q2 2026 net loss $19.6M ($0.11/share) vs $9.9M loss in Q2 2025; R&D spend up to $13.4M from $5.3M.
Cash, equivalents, and marketable securities $159.0M at June 30, 2026; plus $50M gross from 25M shares sold to RA Capital in July 2026.
FDA granted Orphan Drug Designation for IKT-001 in July 2026; Phase 3 IMPROVE-PAH approvals in 26 countries, 43 sites initiated.
Company expects existing and new capital to fund operations through Part B topline data readout, assuming warrant exercise.
Pre-clinical/Phase 1 data at ATS showed improved GI profile vs imatinib and 18-fold lower c-Kit inhibition.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.